Edward S. Kim, MD, MBA

Articles

ADCs in NSCLC: Audience Q&A

August 8th 2022

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.

The Impact of ADCs on Non-Small Cell Lung Cancer Treatment

August 2nd 2022

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

ADCs in Non-Small Cell Lung Cancer

July 21st 2022

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

ADC Technology and Mechanism of Action

July 13th 2022

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.